Lupin gets tentative nod for Rivaroxaban Tablets

24 Jan 2024 Evaluate

Lupin has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg, and 20 mg, to market a generic equivalent of Xarelto Tablets, 2.5 mg, 10 mg, 15 mg, and 20 mg, of Janssen Pharmaceuticals, Inc. This product will be manufactured at Lupin’s Pithampur facility in India.

Rivaroxaban Tablets USP (RLD Xarelto) had estimated annual sales of $8,249 million in the U.S. (IQVIA MAT November 2023). 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

1658.75 -1.20 (-0.07%)
21-May-2024 11:50 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1531.75
Dr. Reddys Lab 5791.10
Cipla 1418.80
Zydus Lifesciences 1108.15
Lupin 1658.75
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.